Welcome to our dedicated page for Orasure Tech news (Ticker: OSUR), a resource for investors and traders seeking the latest updates and insights on Orasure Tech stock.
OraSure Technologies Inc (OSUR) is a leader in non-invasive diagnostic solutions and molecular testing systems for global healthcare markets. This comprehensive news hub provides investors and healthcare professionals with essential updates on corporate developments, regulatory milestones, and product innovations.
Access timely updates including earnings reports, FDA clearances, clinical trial results, and strategic partnerships. Our curated collection features press releases covering oral fluid diagnostics advancements, molecular testing solutions, and cryosurgical product developments – all critical for assessing the company's market position.
Key content categories include financial performance disclosures, manufacturing expansion announcements, research collaborations, and public health initiatives. The archive serves as a vital resource for tracking OSUR's contributions to HIV testing, substance abuse screening, and genetic material stabilization technologies.
Bookmark this page for streamlined monitoring of OraSure's operational updates and industry leadership in medical device innovation. Check regularly for authoritative information supporting informed analysis of this diagnostic technology pioneer.
OraSure Technologies reported Q4 2022 revenue of $123.1 million, a 94% increase year-over-year, driven by InteliSwab® sales of $88.9 million, up 12% sequentially. The company secured two federal contracts for InteliSwab® and partnered with Quest Diagnostics for saliva collection kits. Q4 GAAP EPS was $0.21, with Non-GAAP EPS at $0.36. A restructuring plan is expected to save $15 million annually, aiming for cash flow breakeven by end of 2024. Cash increased to $111 million. Notably, sales of COVID-19 kits declined by 98% year-over-year.
OraSure Technologies, Inc. (NASDAQ: OSUR) will host its earnings conference call on February 14, 2023, at 5:00 PM ET, to discuss its fourth quarter 2022 financial results and recent business developments. A press release detailing the financial results will be made available at 4:05 PM ET on the same day. Interested parties may register for the teleconference through a link provided in the announcement. The call will also be available via webcast on OraSure’s investor relations page and will be archived for 14 days post-event.
OraSure Technologies (NASDAQ: OSUR) rang the Nasdaq closing bell on December 1, 2022, in honor of World AIDS Day. This day aims to raise awareness about the AIDS epidemic and recognize those lost to the disease. The 2022 theme emphasizes the importance of equity in the fight against HIV. The company has been a significant player in HIV diagnostics since 2002, focusing on providing accessible testing, especially for marginalized communities. OraSure's collaboration with the CDC allows them to supply up to one million OraQuick® In-Home HIV tests to those at higher risk in the U.S.
OraSure Technologies (NASDAQ: OSUR) announced that CFO Ken McGrath will participate in a fireside chat at the Stephens Annual Investment Conference on November 17, 2022, at 9:00 am ET. The event will be webcast live, allowing investors and stakeholders to tune in online. Replays of the presentation will be available on the company's website for 14 days. OraSure specializes in point of care diagnostic tests and offers various health solutions through its subsidiaries, including DNA Genotek and Diversigen.
FAQ
What is the current stock price of Orasure Tech (OSUR)?
What is the market cap of Orasure Tech (OSUR)?
